CA3126295A1 - Lilrb3-binding molecules and uses therefor - Google Patents
Lilrb3-binding molecules and uses therefor Download PDFInfo
- Publication number
- CA3126295A1 CA3126295A1 CA3126295A CA3126295A CA3126295A1 CA 3126295 A1 CA3126295 A1 CA 3126295A1 CA 3126295 A CA3126295 A CA 3126295A CA 3126295 A CA3126295 A CA 3126295A CA 3126295 A1 CA3126295 A1 CA 3126295A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- amino acid
- acid sequence
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962794064P | 2019-01-18 | 2019-01-18 | |
| US62/794,064 | 2019-01-18 | ||
| PCT/CA2020/050042 WO2020146946A1 (en) | 2019-01-18 | 2020-01-16 | Lilrb3-binding molecules and uses therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3126295A1 true CA3126295A1 (en) | 2020-07-23 |
Family
ID=71612981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3126295A Pending CA3126295A1 (en) | 2019-01-18 | 2020-01-16 | Lilrb3-binding molecules and uses therefor |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12404327B2 (enExample) |
| EP (1) | EP3911680A4 (enExample) |
| JP (1) | JP7631203B2 (enExample) |
| KR (1) | KR20210118116A (enExample) |
| CN (1) | CN113454123A (enExample) |
| AU (1) | AU2020209367A1 (enExample) |
| BR (1) | BR112021014102A2 (enExample) |
| CA (1) | CA3126295A1 (enExample) |
| EA (1) | EA202192008A1 (enExample) |
| IL (1) | IL284781A (enExample) |
| MX (1) | MX2021008507A (enExample) |
| SG (1) | SG11202107663UA (enExample) |
| TW (1) | TWI852980B (enExample) |
| WO (1) | WO2020146946A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI832183B (zh) * | 2019-08-06 | 2024-02-11 | 香港商新旭生技股份有限公司 | 結合至病理性tau種類之抗體及其用途 |
| CN116963747A (zh) * | 2020-12-03 | 2023-10-27 | 德克萨斯大学体系董事会 | 用于鉴定lilrb阻断抗体的方法 |
| EP4255451A4 (en) * | 2020-12-03 | 2025-01-01 | The Board Of Regents Of The University Of Texas System | Methods for identifying lilrb-blocking antibodies |
| CN115925941B (zh) * | 2022-06-08 | 2026-04-03 | 北京科诺信诚科技有限公司 | 靶向人lilrb4的纳米抗体及其应用 |
| WO2025231127A1 (en) * | 2024-05-02 | 2025-11-06 | The Regents Of The University Of California | Compositions and methods for intracellular antigen targeting with antibodies |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JP2007512846A (ja) | 2003-12-04 | 2007-05-24 | ゼンコー・インコーポレイテッド | 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物 |
| JP5947727B2 (ja) | 2010-01-20 | 2016-07-06 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 抗ｉｌｔ５抗体およびｉｌｔ５結合抗体断片による免疫調節 |
| AU2011207253B2 (en) * | 2010-01-20 | 2015-02-12 | Merck Sharp & Dohme Corp. | Anti-ILT5 antibodies and ILT5-binding antibody fragments |
| AU2013234046B2 (en) | 2012-03-16 | 2017-09-07 | University Health Network | Methods and compositions for modulating Toso activity |
| US20150174203A1 (en) | 2012-05-30 | 2015-06-25 | Icahn School Of Medicine At Mount Sinai | Compositions And Methods For Modulating Pro-Inflammatory Immune Response |
| CA2917077A1 (en) | 2013-07-03 | 2015-01-08 | University Health Network | Antibodies to toso |
| CA2961439A1 (en) | 2014-11-05 | 2016-05-12 | Genentech, Inc. | Anti-fgfr2/3 antibodies and methods using same |
| EP3256163A4 (en) * | 2015-02-11 | 2018-10-10 | University Health Network | Methods and compositions for modulating lilr proteins |
| CN107660150B (zh) * | 2015-03-05 | 2023-10-24 | Ab2生物股份有限公司 | Il-18结合蛋白(il-18bp)和抗体在炎性疾病中 |
| CA3218106A1 (en) * | 2015-03-06 | 2016-09-15 | The Board Of Regents Of The University Of Texas System | Anti-lilrb antibodies and their use in detecting and treating cancer |
| US11787858B2 (en) * | 2016-12-22 | 2023-10-17 | Icahn School Of Medicine At Mount Sinai | Anti-LILRB3 antibodies and methods of use thereof |
-
2020
- 2020-01-16 EP EP20741290.9A patent/EP3911680A4/en active Pending
- 2020-01-16 EA EA202192008A patent/EA202192008A1/ru unknown
- 2020-01-16 AU AU2020209367A patent/AU2020209367A1/en not_active Abandoned
- 2020-01-16 US US17/421,705 patent/US12404327B2/en active Active
- 2020-01-16 SG SG11202107663UA patent/SG11202107663UA/en unknown
- 2020-01-16 BR BR112021014102-2A patent/BR112021014102A2/pt not_active Application Discontinuation
- 2020-01-16 WO PCT/CA2020/050042 patent/WO2020146946A1/en not_active Ceased
- 2020-01-16 JP JP2021541292A patent/JP7631203B2/ja active Active
- 2020-01-16 MX MX2021008507A patent/MX2021008507A/es unknown
- 2020-01-16 TW TW109101527A patent/TWI852980B/zh active
- 2020-01-16 KR KR1020217026164A patent/KR20210118116A/ko not_active Ceased
- 2020-01-16 CN CN202080015060.4A patent/CN113454123A/zh active Pending
- 2020-01-16 CA CA3126295A patent/CA3126295A1/en active Pending
-
2021
- 2021-07-12 IL IL284781A patent/IL284781A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021014102A2 (pt) | 2021-09-21 |
| US20220089723A1 (en) | 2022-03-24 |
| MX2021008507A (es) | 2021-09-21 |
| TW202031685A (zh) | 2020-09-01 |
| KR20210118116A (ko) | 2021-09-29 |
| WO2020146946A1 (en) | 2020-07-23 |
| US12404327B2 (en) | 2025-09-02 |
| JP2022517809A (ja) | 2022-03-10 |
| SG11202107663UA (en) | 2021-08-30 |
| AU2020209367A1 (en) | 2021-08-19 |
| TWI852980B (zh) | 2024-08-21 |
| JP7631203B2 (ja) | 2025-02-18 |
| EA202192008A1 (ru) | 2021-10-21 |
| IL284781A (en) | 2021-08-31 |
| CN113454123A (zh) | 2021-09-28 |
| EP3911680A1 (en) | 2021-11-24 |
| EP3911680A4 (en) | 2022-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7596298B2 (ja) | 免疫応答を調節するためおよび疾患を処置するためのｂｔｌａ結合（ｃｄ２７２）抗体 | |
| US12404327B2 (en) | LILRB3-binding molecules and uses therefor | |
| US20220153834A1 (en) | Tsg-6 antibodies and uses therefor | |
| US20240150462A1 (en) | Lilrb1 and lilrb2-binding molecules and uses therefor | |
| US12286476B2 (en) | FCMR-binding molecules and uses thereof | |
| EA046937B1 (ru) | Lilrb3-связывающие молекулы и варианты их применения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231229 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250110 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250110 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250110 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250617 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251017 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251215 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251215 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251215 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260227 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260714 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260714 |